CA2760325A1 - Dead bacillus coagulans bacteria and uses thereof for boosting the immune system - Google Patents
Dead bacillus coagulans bacteria and uses thereof for boosting the immune system Download PDFInfo
- Publication number
- CA2760325A1 CA2760325A1 CA2760325A CA2760325A CA2760325A1 CA 2760325 A1 CA2760325 A1 CA 2760325A1 CA 2760325 A CA2760325 A CA 2760325A CA 2760325 A CA2760325 A CA 2760325A CA 2760325 A1 CA2760325 A1 CA 2760325A1
- Authority
- CA
- Canada
- Prior art keywords
- bacillus coagulans
- cells
- cell
- pmn
- cell wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000193749 Bacillus coagulans Species 0.000 title claims description 263
- 210000000987 immune system Anatomy 0.000 title abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 229940054340 bacillus coagulans Drugs 0.000 claims description 245
- 210000004027 cell Anatomy 0.000 claims description 175
- 210000002421 cell wall Anatomy 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 87
- 239000006228 supernatant Substances 0.000 claims description 84
- 239000000047 product Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 39
- 230000001965 increasing effect Effects 0.000 claims description 38
- 210000000822 natural killer cell Anatomy 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 206010057249 Phagocytosis Diseases 0.000 claims description 25
- 230000008782 phagocytosis Effects 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 19
- 108090000695 Cytokines Proteins 0.000 claims description 19
- 108010002350 Interleukin-2 Proteins 0.000 claims description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 230000016396 cytokine production Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 230000037451 immune surveillance Effects 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 9
- 230000012292 cell migration Effects 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 210000000224 granular leucocyte Anatomy 0.000 claims description 6
- 244000000010 microbial pathogen Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 230000011268 leukocyte chemotaxis Effects 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000725681 Swine influenza virus Species 0.000 claims description 2
- 210000003622 mature neutrocyte Anatomy 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 12
- 239000004310 lactic acid Substances 0.000 abstract description 6
- 235000014655 lactic acid Nutrition 0.000 abstract description 6
- 230000005012 migration Effects 0.000 description 65
- 238000013508 migration Methods 0.000 description 65
- 210000004215 spore Anatomy 0.000 description 53
- 238000012360 testing method Methods 0.000 description 40
- 230000001580 bacterial effect Effects 0.000 description 36
- 210000004698 lymphocyte Anatomy 0.000 description 34
- 238000010790 dilution Methods 0.000 description 31
- 239000012895 dilution Substances 0.000 description 31
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 239000003226 mitogen Substances 0.000 description 29
- 239000002975 chemoattractant Substances 0.000 description 26
- 102000004890 Interleukin-8 Human genes 0.000 description 25
- 108090001007 Interleukin-8 Proteins 0.000 description 25
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 24
- 229940096397 interleukin-8 Drugs 0.000 description 24
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 24
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 23
- 238000003556 assay Methods 0.000 description 23
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 21
- 108010047620 Phytohemagglutinins Proteins 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 230000001885 phytohemagglutinin Effects 0.000 description 21
- 239000003963 antioxidant agent Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- 230000003110 anti-inflammatory effect Effects 0.000 description 16
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 16
- 230000007646 directional migration Effects 0.000 description 16
- 230000001617 migratory effect Effects 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 14
- 235000018291 probiotics Nutrition 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- 230000006950 reactive oxygen species formation Effects 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000013207 serial dilution Methods 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- -1 e.g. Polymers 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000003399 chemotactic effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000006051 NK cell activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008260 defense mechanism Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 230000031261 interleukin-10 production Effects 0.000 description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 238000010296 bead milling Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000012969 defense response to bacterium Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004040 defense response to microbe Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037457 pro-inflammatory mechanism Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21487609P | 2009-04-29 | 2009-04-29 | |
| US61/214,876 | 2009-04-29 | ||
| US28525509P | 2009-12-10 | 2009-12-10 | |
| US61/285,255 | 2009-12-10 | ||
| PCT/US2010/032993 WO2010127132A1 (en) | 2009-04-29 | 2010-04-29 | Inactivated bacterial cell formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2760325A1 true CA2760325A1 (en) | 2010-11-04 |
Family
ID=42697453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2760325A Abandoned CA2760325A1 (en) | 2009-04-29 | 2010-04-29 | Dead bacillus coagulans bacteria and uses thereof for boosting the immune system |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US8568743B2 (enExample) |
| EP (2) | EP2424550B1 (enExample) |
| JP (3) | JP5836264B2 (enExample) |
| AU (1) | AU2010242955B2 (enExample) |
| CA (1) | CA2760325A1 (enExample) |
| DK (1) | DK2424550T3 (enExample) |
| ES (1) | ES2639364T3 (enExample) |
| HK (1) | HK1247086A1 (enExample) |
| WO (1) | WO2010127132A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2851563B2 (ja) | 1995-05-10 | 1999-01-27 | 株式会社栗本鐵工所 | 水路内面のライニング用補修ユニット及びそのライニング工法 |
| JP2984214B2 (ja) | 1995-09-05 | 1999-11-29 | 株式会社栗本鐵工所 | 既設水路の補修ユニット及びその補修工法 |
| US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| EP2211626B1 (en) | 2007-08-29 | 2019-08-14 | Ganeden Biotech, Inc. | Baked goods |
| DK2348888T3 (en) | 2008-10-16 | 2016-09-12 | Ganeden Biotech Inc | PROBIOTIC CORN-BASED COMPOSITIONS |
| JP5836264B2 (ja) | 2009-04-29 | 2015-12-24 | ガネーデン バイオテック インコーポレイテッド | 不活性化細菌細胞製剤 |
| WO2011130487A1 (en) | 2010-04-14 | 2011-10-20 | Ganeden Biotech, Inc. | Probiotic confection and lipid compositions |
| WO2012135499A1 (en) | 2011-03-31 | 2012-10-04 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
| US20130251695A1 (en) * | 2012-02-28 | 2013-09-26 | Ganeden Biotech, Inc. | Cosmetic Compositions |
| US20150313951A1 (en) * | 2014-05-01 | 2015-11-05 | Ganeden Biotech, Inc. | Functional foods containing bacillus coagulans and non-dairy milk-like compositions |
| DE102017108278B4 (de) * | 2017-04-19 | 2019-03-07 | Bruker Daltonik Gmbh | Mikrobieller Teststandard für die Verwendung in der Infrarot-Spektrometrie |
| US11364268B2 (en) * | 2017-06-21 | 2022-06-21 | Ganeden Biotech, Inc. | Inactivated Bacillus coagulans and uses thereof for increasing physical performance |
| EP3684900B1 (en) * | 2017-09-21 | 2024-11-06 | Sami-Sabinsa Group Limited | Alcoholic beverage composition containing bacillus coagulans |
| WO2019160116A1 (ja) * | 2018-02-16 | 2019-08-22 | イチビキ株式会社 | バチルス属細菌、インターロイキン－２２産生誘導剤、皮膚バリア機能増強剤 |
| WO2019212928A1 (en) * | 2018-04-30 | 2019-11-07 | Muhammed Majeed | Modulation of immune function by bacillus coagulans |
| US12491216B2 (en) | 2018-12-04 | 2025-12-09 | Neiker—Instituto Vasco De Investigacion Y Desarrollo Agrario, S.A. | Immunostimulant for use against pathogens |
| AU2020225473A1 (en) * | 2019-02-22 | 2021-09-30 | Evelo Biosciences, Inc. | Bacterial membrane preparations |
| JP2024175157A (ja) * | 2021-11-12 | 2024-12-18 | 三菱ケミカル株式会社 | 風邪様症状の改善のための組成物 |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3091572A (en) | 1962-07-16 | 1963-05-28 | Schering Corp | Gentamycin and method of production |
| GB1040278A (en) | 1963-10-15 | 1966-08-24 | Analyses Et De Rech S Biolog M | Bacterial compositions for the regeneration of the intestinal microflora |
| US3629073A (en) | 1969-04-01 | 1971-12-21 | Baxter Laboratories Inc | Acid-active lactose |
| US3840684A (en) | 1970-03-13 | 1974-10-08 | Gen Foods Corp | Decaffeinated coffee |
| US3718739A (en) | 1971-06-15 | 1973-02-27 | Baxter Laboratories Inc | Treating lactase deficiency with an active lactase |
| US3919049A (en) | 1974-06-27 | 1975-11-11 | Tokyo Tanabe Co | Process for preparing {62 -galactosidase |
| US4179335A (en) | 1974-12-04 | 1979-12-18 | R. J. Reynolds Tobacco Company | Thermostable lactase derived from Bacillus coagulans |
| US4323651A (en) | 1974-12-04 | 1982-04-06 | R. J. Reynolds Tobacco Company | Thermostable lactase derived from bacillus |
| JPS51150381A (en) | 1975-06-18 | 1976-12-23 | Toshiba Corp | Scanning device for paper-like substance |
| US4210672A (en) | 1976-04-02 | 1980-07-01 | Seikenkai | Preparation of yogurt |
| US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4110477A (en) | 1977-05-13 | 1978-08-29 | Kabushiki Kaisha Naruse Fermentation Laboratory | Method for producing natto containing lactic acid bacteria |
| JPS562908A (en) | 1979-06-20 | 1981-01-13 | Nikken Kagaku Kk | Preparation of stable live bacterial pharmaceutical remedy |
| US4321258A (en) | 1980-08-13 | 1982-03-23 | Dunlap Dorsey S | Non-toxic insecticide |
| CA1206108A (en) | 1981-03-06 | 1986-06-17 | Shuichi Aiba | Process for transforming microorganism by means of plasmid introduction |
| US4751085A (en) | 1984-08-29 | 1988-06-14 | Gaull Gerald E | Human nutritional compositions containing taurine and vitamins and/or minerals |
| FR2569723B1 (fr) | 1984-08-31 | 1986-09-19 | Centre Nat Rech Scient | Application des antibiotiques de la famille des phleomycines a titre d'agent de selection dans le domaine du genie genetique |
| JPH0441434Y2 (enExample) | 1984-09-12 | 1992-09-29 | ||
| JPS61144787A (ja) | 1984-12-17 | 1986-07-02 | Victor Co Of Japan Ltd | 磁気記録再生装置 |
| JPS6261572A (ja) | 1985-09-12 | 1987-03-18 | Nippon Oil & Fats Co Ltd | スプレツドおよびその製法 |
| US4756913A (en) | 1985-09-30 | 1988-07-12 | Khorkova Evgenia A | Sour milk product |
| US4956177A (en) | 1985-11-04 | 1990-09-11 | Microlife Technics, Inc. | Method for inhibiting fungi |
| US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
| JP2806522B2 (ja) | 1987-09-04 | 1998-09-30 | 日本食品化工株式会社 | 分岐フラクトオリゴ糖の製造方法 |
| US4806368A (en) | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
| JPS6483025A (en) | 1987-09-24 | 1989-03-28 | Fujio Hayashi | Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent |
| DK686187D0 (da) | 1987-12-23 | 1987-12-23 | Hansens Chr Bio Syst | Veterinaert praeparat |
| JPH01199575A (ja) | 1988-02-04 | 1989-08-10 | Rikagaku Kenkyusho | 新規なサイクロマルトデキストリン・グルカノトランスフェラーゼ及びその製造法 |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| IT1227154B (it) | 1988-08-05 | 1991-03-19 | A Tosi Farmaceutici S R L Nova | Composizioni farmaceutiche per uso ginecologico a base di lattobacilli |
| AT391323B (de) | 1989-03-10 | 1990-09-25 | Jungbunzlauer Ag | Mikroorganismus der species bacillus coagulans sowie ein verfahren zur herstellung von optisch reiner l(+)-milchsaeure |
| FR2656314B1 (fr) | 1989-12-22 | 1992-04-17 | Bp Chemicals Snc | Catalyseur a base de zirconium supporte sur du chlorure de magnesium, procede de preparation et utilisation du catalyseur dans la polymerisation des olefines. |
| DE4001611C1 (enExample) | 1990-01-20 | 1991-02-28 | Skw Trostberg Ag, 8223 Trostberg, De | |
| US5266315A (en) | 1990-05-07 | 1993-11-30 | Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho | Composite for Clostridium difficile diarrhea and pseudomembranous colitis |
| JPH0678367B2 (ja) | 1990-05-15 | 1994-10-05 | 呉羽化学工業株式会社 | 食物繊維、その製造法及びその食物繊維を含有する生理活性剤 |
| US5200336A (en) | 1990-07-02 | 1993-04-06 | New England Biolabs, Inc. | Restriction endonuclease obtainable foam bacillus coagulans and a process for producing the same |
| FR2677038B1 (fr) | 1991-06-03 | 1994-08-12 | Bel Fromageries | Additif alimentaire pour l'alimentation humaine et animale et aliments le contenant. |
| DE4132296C1 (en) | 1991-09-27 | 1992-12-17 | Karl Heinz 8081 Schoengeising De Hoelzel | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
| GB2261372A (en) | 1991-11-15 | 1993-05-19 | Gregor Reid | Lactobacillus and skim milk compositions for prevention of urogenital infection |
| IT1262927B (it) | 1992-01-14 | 1996-07-22 | Consiglio Nazionale Ricerche | Batteri sporgenti e loro impiego come probiotici |
| CA2063499C (en) | 1992-03-19 | 1996-06-18 | Leon Edward St. Pierre | Ingestible polymeric phosphonium salts for the lowering of blood cholesterol |
| JP3459837B2 (ja) | 1992-05-12 | 2003-10-27 | 太陽化学株式会社 | 生菌粉末 |
| US5902617A (en) | 1992-05-19 | 1999-05-11 | Pabst; Patrea L. | Enzyme supplemented baby formula |
| GB9223709D0 (en) | 1992-11-12 | 1992-12-23 | Ici Plc | Process for the separation of protein from microorganisms |
| WO1994011492A1 (en) | 1992-11-12 | 1994-05-26 | Chr. Hansen's Laboratory, Inc. | Method of favorably modifying poultry intestinal microflora |
| US5449523A (en) | 1993-04-20 | 1995-09-12 | The Ohio State University Research Foundation | Process for the manufacture of a calcium fortified yogurt with improved heat stability |
| US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US6103246A (en) | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
| JP2510943B2 (ja) | 1993-06-07 | 1996-06-26 | 株式会社ドクターマインツ | 痩身用食品 |
| US6428786B1 (en) | 1993-09-28 | 2002-08-06 | Mcneil-Ppc, Inc. | Composition and method for lactose hydrolysis |
| DE4336050C2 (de) | 1993-10-22 | 1995-11-16 | Onken Gmbh | Tierfutter, insbesondere Alleinfutter für Katzen und Hunde |
| JP3381010B2 (ja) | 1994-05-10 | 2003-02-24 | 株式会社林原生物化学研究所 | プロポリスエキスを含有する発酵物とその製造方法並びに用途 |
| US5589381A (en) | 1994-06-30 | 1996-12-31 | Rutgers, The State University Of New Jersey | Bacillus licheniformis producing antifungal agents and uses thereof for control of phytopathogenic fungi |
| AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| US5531988A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
| JPH08175921A (ja) | 1994-12-22 | 1996-07-09 | Idemitsu Kosan Co Ltd | 農園芸用殺菌剤組成物 |
| US5534253A (en) | 1995-06-07 | 1996-07-09 | Biogaia Ab | Method of treating enteropathogenic bacterial infections in poultry |
| US5785990A (en) | 1995-07-10 | 1998-07-28 | Merrick's, Inc. | Feed fortifier and enhancer for preruminant calves and method of using same |
| JPH09194384A (ja) | 1996-01-19 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | ミネラル吸収促進剤 |
| CA2245810A1 (en) | 1996-02-14 | 1997-08-21 | The Procter & Gamble Company | Urogenital and intestinal compositions |
| AUPN881396A0 (en) | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
| JP3658883B2 (ja) | 1996-09-06 | 2005-06-08 | 株式会社ニコン | レンズ鏡筒とその取付部材 |
| ATE206873T1 (de) | 1997-01-09 | 2001-11-15 | Nestle Sa | Probiotik enthaltendes getreideprodukt |
| US6132710A (en) | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
| WO2001034168A1 (en) | 1999-11-08 | 2001-05-17 | Ganeden Biotech, Inc. | Inhibition of pathogens by bacillus coagulans strains |
| US7507402B1 (en) * | 1997-04-18 | 2009-03-24 | Ganeden Biotech, Inc. | Topical use of probiotic Bacillus spores to prevent or control microbial infections |
| EP0975227B1 (en) | 1997-04-18 | 2005-11-09 | Ganeden Biotech, Inc. | Topical use of probiotic bacillus spores to prevent or control microbial infections |
| US6716435B1 (en) | 1997-04-18 | 2004-04-06 | Ganeden Biotech, Inc. | Absorbent product containing absorbent structure and Bacillus coagulans |
| US6645506B1 (en) | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
| JPH10306028A (ja) | 1997-05-06 | 1998-11-17 | Koji Haraguchi | 脂質消化吸収阻害整腸剤 |
| US7374753B1 (en) * | 1997-06-03 | 2008-05-20 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS |
| DE69839993D1 (de) | 1997-06-03 | 2008-10-23 | Ganeden Biotech Inc | Probiotisches milchsäurebakterium zur behandlung bakterieller infektionen in zusammenhang mit sids |
| US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| JP3768694B2 (ja) | 1997-08-18 | 2006-04-19 | コーア株式会社 | Ｂａｃｉｌｌｕｓｓｐ代謝物含有材の製造方法 |
| GB9721139D0 (en) | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| JP3652866B2 (ja) | 1997-12-18 | 2005-05-25 | 花王株式会社 | 有胞子乳酸菌を含有する飲料 |
| US6107291A (en) | 1997-12-19 | 2000-08-22 | Amgen Inc. | Azepine or larger medium ring derivatives and methods of use |
| US5895672A (en) | 1998-01-13 | 1999-04-20 | Cooper; Barry Patrick Wesley | Product and process for preparing a tea extract |
| US5928664A (en) | 1998-02-11 | 1999-07-27 | Fuisz Technologies Ltd. | Consumable gummy delivery system |
| JP3324979B2 (ja) | 1998-02-17 | 2002-09-17 | 浅田商事株式会社 | 芝草の刈りかすおよびサッチを分解するバチルス、そのバチルスを含有する微生物資材 |
| JP3052131U (ja) | 1998-03-10 | 1998-09-14 | 株式会社クレッセンドコーポレーション | ビフィズス菌とオリゴ糖の組合せによるスティック包装袋 |
| US6811786B1 (en) | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| CA2326874C (en) | 1998-04-01 | 2010-05-25 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| JPH11335285A (ja) | 1998-05-25 | 1999-12-07 | Toyotama Koryo Kk | 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料 |
| US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| EP1102595A2 (en) | 1998-08-07 | 2001-05-30 | Ganeden Biotech, Inc. | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| JP2000093162A (ja) | 1998-09-24 | 2000-04-04 | Kao Corp | 有胞子乳酸菌の培養方法 |
| US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| IT1306201B1 (it) | 1999-01-14 | 2001-05-30 | Giuliani Spa | Composizione adatta quale integratore alimentare e per il trattamentoterapeutico di disturbi intestinali e di alterazioni della flora |
| EP1020123A1 (en) | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| WO2000061201A1 (en) | 1999-04-14 | 2000-10-19 | Ganeden Biotech, Inc. | Methods for inhibiting microbial infections associated with sanitary products |
| US20040161422A1 (en) | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
| DE60012026T2 (de) | 1999-08-26 | 2004-12-30 | Ganeden Biotech, Inc., San Diego | Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien |
| JP4082827B2 (ja) | 1999-09-13 | 2008-04-30 | 日東電工株式会社 | 基板の異物除去装置 |
| US6849256B1 (en) * | 1999-11-08 | 2005-02-01 | Ganeden Biotech Incorporated | Inhibition of pathogens by probiotic bacteria |
| ATE320724T1 (de) | 1999-12-30 | 2006-04-15 | Kerry Group Services Ltd | Aufbaupräparat, das kohlenhydrat- und peptidmaterial enthält und sein gebrauch als energieergänzung nach oder während körperlicher übung oder als metabolischer nährstoff für die orale verabreichung |
| JP2001252012A (ja) | 2000-03-15 | 2001-09-18 | Otsuka Shokuhin Kk | 長期間チルド保存可能な乳酸菌飲料およびその製造方法 |
| JP3363438B2 (ja) | 2000-05-02 | 2003-01-08 | ビオフェルミン製薬株式会社 | 噴霧乾燥による菌体乾燥物 |
| MXPA02012743A (es) | 2000-06-22 | 2003-04-25 | Amgen Inc | Moleculas tipo il-17 y usos de las mismas. |
| US20020150594A1 (en) | 2000-06-26 | 2002-10-17 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| US6632028B1 (en) | 2000-08-25 | 2003-10-14 | Vtr Optoelectronics, Inc. | Apparatus and method for aligning an optical fiber with an optical device |
| US7024497B1 (en) | 2000-09-07 | 2006-04-04 | Adaptec, Inc. | Methods for accessing remotely located devices |
| US9292516B2 (en) | 2005-02-16 | 2016-03-22 | Sonic Solutions Llc | Generation, organization and/or playing back of content based on incorporated parameter identifiers |
| JP2002085009A (ja) | 2000-09-14 | 2002-03-26 | Unicafe Inc | 納豆末を用いた腸内活性化食品 |
| JP2002114671A (ja) | 2000-10-04 | 2002-04-16 | Taisho Pharmaceut Co Ltd | サイトカイン産生抑制剤 |
| US20030185811A1 (en) | 2001-02-06 | 2003-10-02 | Steve Teasdale | Herbal extract and preparation thereof |
| WO2002069904A2 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| US6599555B2 (en) | 2001-03-08 | 2003-07-29 | Bocabear Foods, Inc. | Process for making a reduced-calorie fruit and/or vegetable spread |
| US20030124104A1 (en) | 2001-11-05 | 2003-07-03 | Sean Farmer | Probiotic compositions |
| NZ532074A (en) | 2001-11-06 | 2006-02-24 | Maxim Pharm Inc | Compositions for the treatment of infectious diseases |
| EP1344458A1 (en) | 2002-03-12 | 2003-09-17 | Société des Produits Nestlé S.A. | Probiotic delivery system |
| WO2004004747A1 (ja) | 2002-07-09 | 2004-01-15 | Decentwork Inc. | 整腸性組成物及び整腸健康飲料並びに大腸内洗浄液 |
| US20040010510A1 (en) | 2002-07-10 | 2004-01-15 | Timo Hotti | Method and system for database synchronization |
| JP2005536994A (ja) | 2002-07-19 | 2005-12-08 | ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト | イソマルツロースを含むインスタント飲料粉末 |
| TWI228974B (en) | 2002-09-04 | 2005-03-11 | Genmont Biotech Inc | Beverage containing lactobacillus and the manufacturing method thereof |
| US20040071685A1 (en) | 2002-10-09 | 2004-04-15 | Devin Houston | Compositions and methods for increasing the bioavailability of plant polyphenols |
| CN1221187C (zh) | 2002-12-13 | 2005-10-05 | 景岳生物科技股份有限公司 | 含乳酸菌的饮用品及其制造方法 |
| US20040175459A1 (en) | 2003-03-06 | 2004-09-09 | Te-Chih Ting | Method for producing an aqueous beverage containing sporogenous lactic bacteria |
| ATE421256T1 (de) | 2003-03-13 | 2009-02-15 | Kirin Holdings Kk | Probiotische zusammensetzung |
| JP2004337125A (ja) | 2003-05-19 | 2004-12-02 | Ajinomoto Co Inc | 有胞子乳酸菌胞子を含有するインスタントスープ |
| US20050129823A1 (en) | 2003-11-07 | 2005-06-16 | Dohl Christopher T. | Composition and method for making high-protein and low-carbohydrate food products |
| WO2005007179A1 (ja) | 2003-07-18 | 2005-01-27 | Toyo R & D Inc. | ハスの破砕物および／または抽出物と、乳酸菌とを含む組成物 |
| JP2007518394A (ja) | 2003-08-14 | 2007-07-12 | ザ バイオ バランス コーポレイション | 細菌菌株、該細菌菌株を含む組成物、およびそのプロバイオティクス使用 |
| JP2007516667A (ja) | 2003-11-14 | 2007-06-21 | ソニック・ソリューションズ | 書込み可能な媒体への内容の保護された安全な転送 |
| JP2007082403A (ja) | 2004-03-26 | 2007-04-05 | Nippon Medicine:Kk | ユッカ抽出物、キラヤ抽出物及び乳酸菌の複合組成物を含有する飲食品及びその製造法 |
| US7854927B2 (en) | 2004-05-11 | 2010-12-21 | Ganeden Biotech, Inc. | Methods and compositions for the dietary management of autoimmune disorders |
| JP2007308373A (ja) | 2004-06-03 | 2007-11-29 | Toyo Shinyaku:Kk | 腸内菌叢改善剤 |
| JP4296133B2 (ja) | 2004-07-12 | 2009-07-15 | カゴメ株式会社 | チルド飲料およびその製造方法 |
| JP2008521403A (ja) | 2004-11-29 | 2008-06-26 | アロウコープ・インコーポレーテッド | 食品配合物の脱水 |
| EP1854363B8 (en) | 2005-02-23 | 2011-02-23 | Otsuka Pharmaceutical Co., Ltd. | Fermented tea beverage and tea beverage |
| JP4158774B2 (ja) | 2005-03-07 | 2008-10-01 | 株式会社日立製作所 | 再生方法 |
| JP2006254837A (ja) | 2005-03-18 | 2006-09-28 | Kyoto Institute Of Technology | 乳酸菌機能茶、乳酸菌機能茶抽出物、乳酸菌機能茶葉乾燥物 |
| JP2007000140A (ja) | 2005-05-25 | 2007-01-11 | Suntory Ltd | 乳酸菌を用いたコーヒー生豆の処理方法 |
| JP4332743B2 (ja) | 2005-08-12 | 2009-09-16 | 天野実業株式会社 | 発酵食品由来の有胞子性乳酸菌を含有する乾燥食品 |
| US7555715B2 (en) | 2005-10-25 | 2009-06-30 | Sonic Solutions | Methods and systems for use in maintaining media data quality upon conversion to a different data format |
| KR20080068912A (ko) | 2005-11-18 | 2008-07-24 | 이데미쓰 고산 가부시키가이샤 | 바실루스 츄린겐시스를 함유하는 유해균의 방제제 |
| US7758906B2 (en) | 2006-01-20 | 2010-07-20 | Kraft Foods Global Brands Llc | Thickening system for products prepared with milk |
| JP5232404B2 (ja) * | 2006-06-07 | 2013-07-10 | 第一三共ヘルスケア株式会社 | 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物 |
| US7553486B2 (en) | 2006-11-13 | 2009-06-30 | Paul Theodore Finger | Anti-VEGF treatment for radiation-induced vasculopathy |
| US20080166449A1 (en) | 2006-11-29 | 2008-07-10 | Cadbury Adams Usa Llc | Confectionery compositions including an elastomeric component and a saccharide component |
| BRPI0808145A2 (pt) * | 2007-02-28 | 2021-03-23 | Mead Johnson Nutrition Company | Produto contendo probiótico inativado para crianças ou lactentes. |
| US20100098806A1 (en) | 2007-03-13 | 2010-04-22 | Vdf Futureceuticals, Inc. | Compositions and Methods of Dehydrated Food Fortification |
| US20080305096A1 (en) | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
| US20090191609A1 (en) * | 2007-08-29 | 2009-07-30 | Lefkowitz Andrew R | Compositions and methods for enhancing paper product degradation |
| EP2211626B1 (en) | 2007-08-29 | 2019-08-14 | Ganeden Biotech, Inc. | Baked goods |
| ES2868135T3 (es) | 2007-10-16 | 2021-10-21 | Ganeden Biotech Inc | Composiciones de bebidas |
| US20090202683A1 (en) | 2008-02-11 | 2009-08-13 | Jennyfer Reed Matteson | Confections with chewy, sour and creamy attributes, and methods to make and use the same |
| DK2348888T3 (en) | 2008-10-16 | 2016-09-12 | Ganeden Biotech Inc | PROBIOTIC CORN-BASED COMPOSITIONS |
| JP5836264B2 (ja) | 2009-04-29 | 2015-12-24 | ガネーデン バイオテック インコーポレイテッド | 不活性化細菌細胞製剤 |
| WO2011130487A1 (en) | 2010-04-14 | 2011-10-20 | Ganeden Biotech, Inc. | Probiotic confection and lipid compositions |
| WO2012135499A1 (en) | 2011-03-31 | 2012-10-04 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
| US20150044317A1 (en) | 2012-02-28 | 2015-02-12 | Ganeden Biotech, Inc. | Topical Compositions for Reducing Visible Signs of Aging and Methods of Use Thereof |
| US20130251695A1 (en) | 2012-02-28 | 2013-09-26 | Ganeden Biotech, Inc. | Cosmetic Compositions |
| US20150313951A1 (en) | 2014-05-01 | 2015-11-05 | Ganeden Biotech, Inc. | Functional foods containing bacillus coagulans and non-dairy milk-like compositions |
-
2010
- 2010-04-29 JP JP2012508737A patent/JP5836264B2/ja not_active Expired - Fee Related
- 2010-04-29 ES ES10717388.2T patent/ES2639364T3/es active Active
- 2010-04-29 WO PCT/US2010/032993 patent/WO2010127132A1/en not_active Ceased
- 2010-04-29 DK DK10717388.2T patent/DK2424550T3/en active
- 2010-04-29 EP EP10717388.2A patent/EP2424550B1/en not_active Not-in-force
- 2010-04-29 AU AU2010242955A patent/AU2010242955B2/en not_active Ceased
- 2010-04-29 EP EP17167269.4A patent/EP3246039A1/en not_active Withdrawn
- 2010-04-29 CA CA2760325A patent/CA2760325A1/en not_active Abandoned
- 2010-04-29 US US12/770,457 patent/US8568743B2/en not_active Expired - Fee Related
-
2012
- 2012-09-13 US US13/613,316 patent/US8568744B2/en not_active Expired - Fee Related
-
2013
- 2013-10-28 US US14/064,863 patent/US9192659B2/en active Active
-
2015
- 2015-07-06 JP JP2015134864A patent/JP6133937B2/ja not_active Expired - Fee Related
- 2015-11-23 US US14/949,362 patent/US9446111B2/en active Active
-
2016
- 2016-09-16 US US15/268,276 patent/US9757442B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 JP JP2017083493A patent/JP6419253B2/ja not_active Expired - Fee Related
- 2017-09-11 US US15/700,925 patent/US20180153980A1/en not_active Abandoned
-
2018
- 2018-05-21 HK HK18106537.7A patent/HK1247086A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1247086A1 (en) | 2018-09-21 |
| US20130011439A1 (en) | 2013-01-10 |
| US9446111B2 (en) | 2016-09-20 |
| US9192659B2 (en) | 2015-11-24 |
| JP6133937B2 (ja) | 2017-05-24 |
| EP2424550A1 (en) | 2012-03-07 |
| US20180153980A1 (en) | 2018-06-07 |
| US8568743B2 (en) | 2013-10-29 |
| EP3246039A1 (en) | 2017-11-22 |
| EP2424550B1 (en) | 2017-06-07 |
| JP2015212289A (ja) | 2015-11-26 |
| ES2639364T3 (es) | 2017-10-26 |
| US20160074495A1 (en) | 2016-03-17 |
| JP2012525428A (ja) | 2012-10-22 |
| US20100297092A1 (en) | 2010-11-25 |
| DK2424550T3 (en) | 2017-08-28 |
| US20170000872A1 (en) | 2017-01-05 |
| AU2010242955B2 (en) | 2016-02-04 |
| JP5836264B2 (ja) | 2015-12-24 |
| JP6419253B2 (ja) | 2018-11-07 |
| US8568744B2 (en) | 2013-10-29 |
| AU2010242955A1 (en) | 2011-11-24 |
| JP2017125064A (ja) | 2017-07-20 |
| US20140050764A1 (en) | 2014-02-20 |
| WO2010127132A1 (en) | 2010-11-04 |
| US9757442B2 (en) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9757442B2 (en) | Inactivated bacterial cell formulation | |
| Jensen et al. | GanedenBC30™ cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro | |
| Meidong et al. | Evaluation of probiotic Bacillus aerius B81e isolated from healthy hybrid catfish on growth, disease resistance and innate immunity of Pla-mong Pangasius bocourti | |
| Adel et al. | Effects of dietary Spirulina platensis on growth performance, humoral and mucosal immune responses and disease resistance in juvenile great sturgeon (Huso huso Linnaeus, 1754) | |
| Nantz et al. | Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention | |
| Chalamaiah et al. | Immunomodulatory effects of protein hydrolysates from rohu (Labeo rohita) egg (roe) in BALB/c mice | |
| CN102168043B (zh) | 可作为免疫调节剂的副干酪乳酸杆菌lt12 | |
| CN101171019A (zh) | 免疫功能调节剂 | |
| Laskowska et al. | The effect of feed supplementation with effective microorganisms (EM) on pro-and anti-inflammatory cytokine concentrations in pigs | |
| Dias et al. | Comparative effects of using a single strain probiotic and multi-strain probiotic on the productive performance and disease resistance in Oreochromis niloticus | |
| EP2220210A1 (en) | Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect | |
| KR102525173B1 (ko) | 바실루스속 세균, 인터류킨-22 산생 유도제, 피부 장벽 기능 증강제 | |
| US20180280450A1 (en) | Method of promoting immune health using the water-soluble component from genus euglena organism | |
| Zimmermann et al. | Macroencapsulation of Limosilactobacillus reuteri DSPV002C as nutritional supplement for piglets: Storage stability and survival in gastrointestinal conditions | |
| Dvorožňáková et al. | Modulation of lymphocyte subpopulations in the small intestine of mice treated with probiotic bacterial strains and infected with Trichinella spiralis | |
| Guo et al. | Lactobacillus plantarum antimicrobial peptide Y8-2: A new strategy against Toxoplasma gondii | |
| Soleimani et al. | The overlooked hazard: Clostridioides difficile in preterm infants and immature immune systems—harnessing postbiotics for safer therapeutic strategies | |
| KR20240072336A (ko) | 병원균에 대한 감염 예방 및 면역증진 활성을 가지는 신규한 바실러스 서브틸리스 jb15 균주 및 이의 용도 | |
| CN118524845A (zh) | T细胞的分化调节剂和组合物 | |
| KR20150045137A (ko) | 바실러스 아밀로리퀴페시언스 26n 균주를 유효성분으로 포함하는 항알레르기성 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150102 |
|
| FZDE | Discontinued |
Effective date: 20220823 |
|
| FZDE | Discontinued |
Effective date: 20220823 |